Head-To-Head Review: MediWound (MDWD) versus Peregrine Pharmaceuticals (NASDAQ:PPHM)
Peregrine Pharmaceuticals (NASDAQ: PPHM) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitabiliy.
Institutional and Insider Ownership
86.8% of Peregrine Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.3% of MediWound shares are owned by institutional investors. 4.9% of Peregrine Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Peregrine Pharmaceuticals and MediWound’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Peregrine Pharmaceuticals has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Peregrine Pharmaceuticals and MediWound, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Peregrine Pharmaceuticals presently has a consensus price target of $5.25, suggesting a potential upside of 32.91%. MediWound has a consensus price target of $11.67, suggesting a potential upside of 67.87%. Given MediWound’s stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Peregrine Pharmaceuticals.
Earnings & Valuation
This table compares Peregrine Pharmaceuticals and MediWound’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Peregrine Pharmaceuticals||$57.63 million||3.09||-$25.80 million||($0.93)||-4.25|
|MediWound||$1.84 million||82.83||-$19.19 million||($0.75)||-9.27|
MediWound has higher revenue, but lower earnings than Peregrine Pharmaceuticals. MediWound is trading at a lower price-to-earnings ratio than Peregrine Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Peregrine Pharmaceuticals beats MediWound on 7 of the 13 factors compared between the two stocks.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Receive News & Stock Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.